Enzyme-substrate-inactivator complex formation can impact time-dependent inhibition kinetics

Drug Metab Dispos. 2026 Apr;54(4):100257.
doi: 10.1016/j.dmd.2026.100257. Epub 2026 Feb 19.
Jaydeep Yadav 1, Jan Wahlstrom 2, Ken Korzekwa 3, Swati Nagar 3

Future directions in drug-drug interaction evaluations: Industry perspective on the ICH M12 guidance

Drug Metab Pharmacokinet. 2026 Feb:66:101512.
doi: 10.1016/j.dmpk.2025.101512. Epub 2025 Dec 12.
Kenichi Umehara 1, Andrew Harrell 2, Chandra Prakash 3, Constanze Hilgendorf 4, T Eric Ballard 5, Felix Huth 6, Justine Badée 6, Licong Jiang 7, Manoli Vourvahis 8, Natasa Pajkovic 9, Neil Parrott 10, Nilay Thakkar 11, Patrik Marroum 12, Ronald Laethem 13, Shiyao Xu 14, Yuan Chen 15

Human absorption, distribution, metabolism, excretion, and reaction phenotyping of ervogastat (PF-06865571), a diacylglycerol O-acyltransferase 2 inhibitor

Drug Metab Dispos. 2026 May;54(5):100286.
doi: 10.1016/j.dmd.2026.100286. Epub 2026 Mar 30.
Manoli Vourvahis 1, Christine C Orozco 2, David Tess 3, Yizhong Zhang 4, Jonathan N Bauman 2, James R Gosset 3, Neeta B Amin 5, Matthew A Cerny 6

Molnupiravir is not a selective CES2 probe substrate: in vitro evidence for CES1 involvement

Drug Metab Dispos. 2026 May;54(5):100281.
doi: 10.1016/j.dmd.2026.100281. Epub 2026 Mar 25.
Luke Roberts 1, Hannah Moulton 1, Xiaofeng Wu 1, Benjamin Quell 1, Nicholas Ferguson 1, Brendon Kapinos 1, Matthew A Cerny 1, Lloyd Wei Tat Tang 2

Prevalence of non-cytochrome P450-mediated metabolism in food and drug administration-approved drugs: 2005-2024

Review
Drug Metab Dispos. 2026 Mar;54(3):100234.
doi: 10.1016/j.dmd.2026.100234. Epub 2026 Mar 14.
Matthew A Cerny 1

In vitro reversible enzyme inhibition assays to predict drug-drug interactions: Current state and industry perspective from the IQ Consortium Enzyme Inhibition Working Group

Drug Metab Dispos. 2026 Jun;54(6):100325.
doi: 10.1016/j.dmd.2026.100325. Epub 2026 May 14.
Carlo Sensenhauser 1, Sarah M Glass 2, Upendra P Dahal 3, Guanfa Gan 4, Theunis C Goosen 5, Constanze Hilgendorf 6, Kishore Katyayan 7, Mike Mohutsky 8, Rune Aa Nørgaard 9, Dung Nguyen 10, Chandra Prakash 11, Hilmar Schiller 12, Raku Shinkyo 13, David M Stresser 14, Kenichi Umehara 15, Michael R Wester 16, Beth Williamson 17

From Lead to Clinical Candidate: Discovery of BMS-986331 as a Potent and Selective N-Formyl Peptide Receptor 2 Agonist

J Med Chem. 2026 Feb 26;69(4):4078-4089.
doi: 10.1021/acs.jmedchem.5c02712. Epub 2026 Feb 17.
Pravin S Shirude 1, Daniel Cheney 2, Amit K Chattopadhyay 3, Balaji Seshadri 3, Vishweshwaraiah Baligar 3, Chandrasekhar Rachamreddy 3, Sudhakara Madduri 3, Prakash Anjanappa 3, Andrew Viet 2, Meriah N Valente 2, Karen Rossi 2, Mojgan Abousleiman 2, Mei-Yin Hsu 2, Gerry Everlof 2, Volodymyr Gali 2, Yongnian Sun 2, John Allocco 2, Rongan Zhang 2, Stéphane St-Onge 4, John Lupisella 2, Xue-Qing Chen 2, Sanket Sarodaya 3, Madhu Sudhan Ravindran 1, Debarati M Tagore 1, Jignesh Nagar 3, Shailesh Dudhgaonkar 1, Sivaprasad Putlur 3, Madeleine Héroux 4, Michel Bouvier 4, Ruth R Wexler 2, Elizabeth Dierks 2, Ricardo A Garcia 2, Ellen K Kick 2, Nicholas R Wurtz 2

2025 White Paper on Recent Issues in Bioanalysis: What is the Future of Bioanalytical LIMS? AI/ML Integration in Bioanalysis; Tear Sample Collection; Radiolabeled Mass Balance Studies; Chiral Assays; Bioanalysis of Antibody-Oligonucleotide & Bicycle Drug Conjugates (PART 1A – Recommendations on Mass Spectrometry Assays, Chromatography, Sample Preparation and Regulated Bioanalysis Sampling, Validating, Analyzing & Reporting PART 1B – Regulatory Agencies’ Input on Regulated Bioanalysis/BMV)

Bioanalysis. 2025 Dec;17(24):1605-1654.
doi: 10.1080/17576180.2026.2617084. Epub 2026 Feb 13.
John Wojcik 1, Mark Qian 2, Anton I Rosenbaum 3, Estelle Maes 4, Yongjun Xue 5, Christopher Kochansky 6, Jason Boer 7, Linzhi Chen 8, Sandrine Descloux 9, Fabio Garofolo 10, Jay Johnson 11, Surinder Kaur 12, Michael Lassman 1, Jessica McGregor 13, Lisa O’Callaghan 1, Timothy Sikorski 14, Katty Wan 15, Shunhai Wang 16, Naiyu Zheng 5, Guodong Zhang 17, Michael Hoover 18, Jian Wang 19, Long Yuan 20, Qin Ji 4, Barry Jones 19, Ramakrishna Boyanapalli 5, Jian Chen 5, Christine Dobson 21, Linlin Dong 2, Luca Ferrari 22, Yunlin Fu 23, Chao Gong 18, Dany Ivanova 21, Jing Li 17, Hermes Licea-Perez 14, Aihua Liu 24, Xiaonan Tang 25, Lin Tao 26, Joseph Tweed 27, John Eddy 28, Jennifer Francis 16, Olga Kavetska 29, Marcela Araya 11, Timothy Foley 2, Matthew Andisik 16, Mary Belfast 30, Lisa Borbridge 31, Seongeun Julia Cho 32, Liliana Colligan 16, Arindam Dasgupta 32, Anna Edmison 21, Christine Fandozzi 33, Fabrizio Galliccia 34, Yeoun Jin Kim 18, Yang Lu 32, Anne-Marie Massip 35, Diaa Shakleya 32, Nilufer Tampal 32, Joao Tavares Neto 36, Justina Thomas 1, Jin Wang 37, Linna Wang 19, Ying Wang 11, Emma Whale 35, Megan Wiberg 38, Li Yang 32

Transporter-transporter interplay determines the renal-predominant elimination of the O-glucuronide metabolite (BI 689875) of vicadrostat in humans

Drug Metab Dispos. 2026 Feb;54(2):100228.
doi: 10.1016/j.dmd.2025.100228. Epub 2025 Dec 26.
Pallabi Mitra 1, Rumanah Shah 2, Laeticia Iboki 2, Zachary Williams 2, Hlaing Holly Maw 2, Ting Wang 2, Matt Hrapchak 3, Bachir Latli 3, Raimund Kuelzer 4, Naoki Ishiguro 4, Ryo Takahashi 5, Takashi Kudo 5, Akiko Matsui 5, Mitchell E Taub 2

Drug-drug interaction assessments of clinical transporter inhibition: Learnings from the Transporter Working Group of the International Consortium for Innovation and Quality in Pharmaceutical Development

Drug Metab Dispos. 2026 Apr;54(4):100255.
doi: 10.1016/j.dmd.2026.100255. Epub 2026 Feb 24.
Rucha S Sane 1, Pallabi Mitra 2, Yurong Lai 3, Cindy Yanfei Li 4, Hong Shen 5, Kimio Tohyama 6, Chester Costales 7, Laurent Salphati 8, Kelly M Mahar 9, Daniel A J Bow 10, James M Vergis 11, Jochen Brumm 12, Kunal Taskar 13, Hugues Chanteux 14, Zhizhou Fang 15, Xiaomin Liang 3, Seong Hee Park 16, Imad Hanna 17, Nilay Thakkar 9, Xiaoyan Chu 18, Cornelis E C A Hop 8, Helen E Rollison 19, Mitchell E Taub 2, Emi Kimoto 7, Katherine S Fenner 19, Christine Xu 20, Kathleen M Hillgren 21

Discovery of the Orally Bioavailable Isoform Selective Janus Kinase 1 (JAK1) Compound Povorcitinib (INCB054707) for the Treatment of Inflammatory and Autoimmune Diseases

J Med Chem. 2026 Jun 11;69(11):12830-12852.
doi: 10.1021/acs.jmedchem.5c03753. Epub 2026 May 27.
Jincong Zhuo 1, Yun-Long Li 1, Ding-Quan Qian 1, David M Burns 1, Song Mei 1, Maria Rafalski 1, Meizhong Xu 1, Ganfeng Cao 1, Yongchun Pan 1, Zhongjiang Jia 1, Ravi Jalluri 1, Leslie B Epling 1, Gustavo Fenalti 1, Marc C Deller 1, Jessica Procak 1, Maryanne Covington 1, Xin He 1, Robert Collins 1, Matthew Stubbs 1, Krista Burke 1, Julian Oliver 1, Alex Margulis 1, Jason Boer 1, Richard Wynn 1, Peggy Scherle 1, Sharon Diamond 1, Robert Newton 1, Yan Zhang 1, Brian Metcalf 1, Wenqing Yao 1

Rapid assessment of metabolism and disposition of conjugated oligonucleotide vutrisiran in rats using a sensitive LC-HRMS platform.

Drug Metab Dispos. 2026 Jun;54(6):100305.
doi: 10.1016/j.dmd.2026.100305. Epub 2026 Apr 17.
Peng Li1, Xianqing Yu 1, Jiamin Wu 1, Gengyao Qin 2, Hong Zhang 2, Weiqun Cao 3, Mingshe Zhu 4, Liang Shen 4, Yi Tao 5

In vitro metabolism studies of 5 acrylamide covalent drugs: Comparison with metabolism and disposition in human.

Drug Metab Dispos. 2026 Mar;54(3):100239.
doi: 10.1016/j.dmd.2026.100239. Epub 2026 Jan 17.
Ruixing Li1, Qingfeng Shi 1, Mingshe Zhu 2, Weiqun Cao 3, Yi Tao 4, Liang Shen 1

A universal LC-HRMS workflow integrating targeted and untargeted strategies for rapid and comprehensive metabolite profiling of oligonucleotide-based therapeutics.

J Pharm Biomed Anal. 2026 Mar 15;270:117298.
doi: 10.1016/j.jpba.2025.117298. Epub 2025 Dec 4.
Yuqing Zhao1, Yue Yang 2, Mingshe Zhu 3, Chongzhuang Tang 4